US · YI · MEDICAL - DISTRIBUTION
111, Inc. (YI) intrinsic value and stock valuation
$2.36as of 2026-11-21 · Mkt cap 32.32M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
111, Inc. DCF and intrinsic value
InvestorsCraft values YI with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from YI’s statements →
111, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $12.2B | $14.4B | $14.9B | $13.5B | $12.4B |
| Operating income | -$-10.03M | $2.11M | -$-350.1M | -$-371M | -$-642.14M |
| Net income | -$-16.84M | -$-64.74M | -$-392.69M | -$-416.88M | -$-669.81M |
| EPSd | -$-1.94M | -$-7.51M | -$-46.58M | -$-50.05M | -$-80.8M |
| Operating cash flow | $119.1M | $263M | -$-447.24M | -$-23.15M | -$-688.84M |
| Capital expenditure | -$-4.45M | -$-15.2M | -$-9.82M | -$-31.57M | -$-62.69M |
| Free cash flow | $114.7M | $247.8M | -$-457.07M | -$-54.73M | -$-751.53M |
| Total assets | $2.2B | $2.79B | $3.09B | $3.47B | $3.15B |
| Total debt | $217.7M | $256.8M | $443.2M | $344.2M | $491M |
| Net debt | -$-343.93M | -$-205.52M | -$-160.29M | -$-329.48M | -$-170.38M |
| Total equity | $214.6M | $380.8M | $276.1M | $648.2M | $848.7M |
| Cash and short-term investments | $611.7M | $462.3M | $653.7M | $879.5M | $844M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $12.2B | $14.4B | $14.9B | $13.5B | $12.4B |
| Cost of revenue | $11.5B | $13.6B | $14.1B | $12.7B | $11.8B |
| Gross profit | $703.7M | $829.2M | $849M | $840M | $621.1M |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $655M | $384.8M | $672.6M | $663.5M | $720.1M |
| Other expenses | $58.8M | $442.3M | $526.5M | $547.5M | $543.1M |
| Operating expenses | $713.7M | $827.1M | $1.2B | $1.21B | $1.26B |
| Cost and expenses | $12.2B | $14.4B | $15.3B | $13.9B | $13.1B |
| Interest income | $3.78M | $7.04M | $8.83M | $8.12M | $9.78M |
| Interest expense | $34.6M | $28.3M | $20.1M | $13.4M | $5.49M |
| Depreciation and amortization | $11.8M | $17M | $21.8M | $40.8M | $27.2M |
| Ebitda | $1.81M | $24.6M | -$-311.26M | -$-321.81M | -$-588.32M |
| Operating income | -$-10.03M | $2.11M | -$-350.1M | -$-371M | -$-642.14M |
| Total other income/expenses, net | -$-11.86M | -$-22.79M | -$-3.08M | -$-5.07M | $21.1M |
| Income before tax | -$-21.89M | -$-20.68M | -$-353.18M | -$-376.07M | -$-621.02M |
| Income tax expense | $10K | $100K | $250K | $0.00 | $0.00 |
| Net income | -$-16.84M | -$-64.74M | -$-392.69M | -$-416.88M | -$-669.81M |
| Weighted average shares outstanding | $8.7M | $8.62M | $8.43M | $8.33M | $8.29M |
| Weighted average diluted shares outstanding | $8.7M | $8.62M | $8.43M | $8.33M | $8.29M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $611.7M | $462.3M | $653.7M | $879.5M | $844M |
| Net receivables | $318.5M | $630.7M | $647.5M | $600.5M | $495.2M |
| Inventory | $999.1M | $1.39B | $1.42B | $1.5B | $1.12B |
| Total current assets | $2.13B | $2.65B | $2.93B | $3.24B | $2.8B |
| Property, plant and equipment, net | $65.3M | $122M | $138.1M | $212.4M | $314.1M |
| Goodwill and intangible assets | $870K | $1.44M | $2.26M | $3.27M | $4.91M |
| Long-term investments | $0.00 | $0.00 | $2M | $2M | $3M |
| Total non-current assets | $75.4M | $138.1M | $155.7M | $238M | $344.1M |
| Total assets | $2.2B | $2.79B | $3.09B | $3.47B | $3.15B |
| Accounts payable | $1.28B | $1.72B | $1.59B | $1.76B | $1.35B |
| Short-term debt | $187.8M | $201.3M | $380.6M | $243.7M | $325.4M |
| Deferred revenue | $0.00 | $185.9M | $193.5M | $323.6M | $202.6M |
| Total current liabilities | $1.95B | $2.34B | $2.75B | $2.73B | $2.13B |
| Long-term debt | $30M | $55.5M | $62.6M | $100.5M | $165.6M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $32.2M | $64.4M | $67.9M | $100.5M | $167.2M |
| Capital lease obligations | $30M | $95.8M | $105.2M | $165.2M | $231.4M |
| Total liabilities | $1.99B | $2.41B | $2.81B | $2.83B | $2.3B |
| Common stock | $60K | $60K | $60K | $60K | $60K |
| Retained earnings | -$-3.95B | -$-3.88B | -$-3.82B | -$-3.43B | -$-3.01B |
| Accumulated other comprehensive income (loss) | $72.7M | $74.4M | $72.5M | $75.6M | $59.4M |
| Total equity | $214.6M | $380.8M | $276.1M | $648.2M | $848.7M |
| Total investments | $50.1M | $0.00 | $52.1M | $207.9M | $185.6M |
| Total debt | $217.7M | $256.8M | $443.2M | $344.2M | $491M |
| Net debt | -$-343.93M | -$-205.52M | -$-160.29M | -$-329.48M | -$-170.38M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-22.52M | -$-20.78M | -$-353.43M | -$-376.07M | -$-621.02M |
| Depreciation and amortization | $11.8M | $17M | $21.8M | $40.8M | $27.2M |
| Stock-based compensation | $10.1M | $20.2M | $226.7M | $162.1M | $145.6M |
| Change in working capital | $77.2M | $192.7M | -$-424.33M | $44.5M | -$-369.87M |
| Accounts receivable | $170.7M | $122M | -$-49.9M | -$-86.98M | -$-242.4M |
| Inventory | $387.1M | $28.1M | $59.6M | -$-406.29M | -$-400.55M |
| Accounts payable | -$-439.06M | $132.7M | -$-176.74M | $417.5M | $274M |
| Net cash provided by operating activities | $119.1M | $263M | -$-447.24M | -$-23.15M | -$-688.84M |
| Investments in property, plant and equipment | -$-4.45M | -$-15.2M | -$-9.82M | -$-31.57M | -$-62.69M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-2.96M | $100K |
| Net cash used for investing activities | -$-53.72M | $37.4M | $151.7M | -$-47.17M | $60.1M |
| Common stock issued | $740K | $10K | $220K | $270K | $2.92M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | -$-5.89M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-21.19M | -$-406.24M | $206M | $22.7M | $74.3M |
| Net change in cash | $43M | -$-105.22M | -$-93.24M | -$-43.88M | -$-557.86M |
| Cash at end of period | $561.3M | $518.3M | $623.6M | $716.8M | $760.7M |
| Operating cash flow | $119.1M | $263M | -$-447.24M | -$-23.15M | -$-688.84M |
| Capital expenditure | -$-4.45M | -$-15.2M | -$-9.82M | -$-31.57M | -$-62.69M |
| Free cash flow | $114.7M | $247.8M | -$-457.07M | -$-54.73M | -$-751.53M |
Line items
Line items
Line items
About 111, Inc.
Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.
- CEO
- Junling Liu
- Employees
- 1.06K
- Beta
- 0.63
Explore
Frequently asked questions
What is the intrinsic value of 111, Inc. (YI)?
111, Inc. (YI) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is YI undervalued?
YI trades at a price of $2.36 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.